Long-term safety concerns of antiresorptive therapy |
| |
| Authors: | Zhang Jie Saag Kenneth G Curtis Jeffrey R |
| |
| Institution: | aHealth Services/Comparative Effectiveness Research Training Program, Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, RPHB 517B, Birmingham, AL 35294, USA;bDivision of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Faculty Office Tower 820, 510 20th Street South, Birmingham, AL 35294, USA;cDivision of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Faculty Office Tower 805D, 510 20th Street South, Birmingham, AL 35294, USA |
| |
| Abstract: | Bisphosphonates reduce the risk of major osteoporotic fractures and are the most commonly used medications for the prevention and treatment of osteoporosis. Although these medications are well tolerated and safe during large-scale clinical trials, several rare and serious adverse events are suspected to be associated with long-term bisphosphonate use. These adverse events include osteonecrosis of the jaw, atypical fractures, and esophageal cancer. This review summarizes studies examining the association between bisphosphonate use and these adverse outcomes, with a focus on large case series and controlled epidemiologic studies. |
| |
| Keywords: | Osteoporosis Anti-resorptive therapy Safety concerns |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
